Report V of Conversations on Planetary Health
The tab is the result of a preliminary landscape of vaccines licensed or under development for Mpox
The tab is the result of a preliminary landscape of therapeutics licensed or under development for Mpox
J of Pharm Policy and Pract 14, 27 (2021). https://doi.org/10.1186/s40545-021-00309-8
Nutrition data and information systems (ND&IS) are critical to guide the prioritisation, collection, analysis and
dissemination of nutrition data in countries. However, there is limited guidance for countries regarding how to invest
in their ND&IS and little is known about current financing alloca
...
tions by both countries and donors
more
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
Practically, planetary health presents a new way to approach and solve problems. For example, there is
alignment at the highest levels with global policy frameworks – primarily the Convention on Biological
Diversity Aichi Biodiversity Targets, the Paris Climate Agreement, and the Sustainable Dev
...
elopment
Goals – which will require collaboration across sectors to make progress. While this alignment validates
integrated concepts like planetary health, it also highlights the need for these concepts to be much
more actionable, so that they can be easily taken up by government decision makers as a way to
achieve goals.
more
Malar J (2017) 16:174 DOI 10.1186/s12936-017-1808-x
Background: Since 2004, artemisinin-based combination therapy (ACT) has been the first-line treatment for uncomplicated malaria in Benin. In 2016, a medicine outlet survey was implemented to investigate the availability, price, and market share of
...
anti-malarial treatment and malaria diagnostics. Results provide a timely and important benchmark to measure future interventions aimed at increasing access to quality malaria case management services.
more
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method
...
ology issues there are still insufficient data to make a recommendation, in which case different options for approaching VE evaluations are presented.
more
ALTER, European Journal of Disability Research 9(2015)317–330.
The purpose of this paper is to describe the varying scope and content of data collection instruments on child disability and to provide a historical snapshot of the rates of reported disability among children. A total of 716 data sou
...
rces were identified, corresponding to 198 countries covering more than 95% of the world’s children. The findings reveal a lack of consistent definitions and measures of disability, which contribute to major challenges in producing reliable and comparable statistics.
more
Many vaccines and drugs hold the promise of reducing mortality and morbidity among pregnant women and infants living in low- and middle-income countries (LMICs). However, sufficient information on the safety of drugs and vaccines in pregnant women is rarely available at the time of product licensure
...
or approval. To account for this, active safety surveillance efforts are needed during the post-licensure and post-approval
phase to assess the safety of drugs and vaccines in pregnant women and their offspring. Pregnancy exposure registries (PER) are used to monitor the safety of vaccines and drugs. PERs are observational studies that systematically collect health information on exposure to medical products such as drugs and vaccines during pregnancy. This review demonstrates that a number of resources presently exist in LMICs that perform active safety surveillance in pregnant populations. These results indicate such systems employ a wide variety of approaches, each with their own set of strengths and challenges, as summarized in the final section of the report.
more
A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform.
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations s
...
till exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address the many outstanding research questions. This systematic review aims to describe the characteristics and treatment practices of clinical studies in CD and assess the breadth and availability of research data for the potential establishment of a data-sharing platform.
more
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address
the many outstanding rese
...
arch questions. This systematic review aims to describe the characteristics and treatment practices of clinical studies in CD and assess the breadth and
availability of research data for the potential establishment of a data-sharing platform.
more
#AIDS2016 | @AIDS_conference
Accessed: 26.09.2019